Halozyme Therapeutics Inc (Halozyme) is a biotechnology company focused on developing and commercializing recombinant human enzymes that improve how biologics and other drugs are delivered.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Halozyme's research and development initiatives focus on product development, quality and regulatory work for maintaining the ENHANZE, Hypercon technology, and Surf Bio technology platforms. The company is involved in testing new high-volume auto-injectors and supporting partners in the development and manufacturing of product candidates. The acquisition of Elektrofi and Surf Bio has contributed to an increase in R&D expenses, with efforts directed towards the development of a new high-yield rHuPH20 manufacturing process. Its R&D activities are supported by facilities in Boston, Massachusetts, which focus on research and development, quality operations, and administrative functions for the Hypercon technology. The company's operations are headquartered in San Diego, California, with additional facilities in Ewing, New Jersey, and Minnetonka, Minnesota. In FY2025, the company spent US$81.4 million on its R&D activities, which as a percentage of revenue stood at 5.8% and grew 3% YoY.